All In Biotech

Drug Trial Radar · NCT06507436

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

The Efficacy and Safety of Herombopag in Treating Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Jul 31, 2024

Primary completion

Aug 14, 2026

Study completion Aug 14, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.

Conditions

  • Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Interventions

  • Herombopag tabletsDrug

    Herombopag tablets; dose 1 or dose 2, for 5 days

  • Herombopag placebo tabletsDrug

    Herombopag placebo tablets; dose 1 or dose 2, for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: CL/FTime frame: 0 minute to 5 days
  2. Part A: Vc/FTime frame: 0 minute to 5 days
  3. Part A: kaTime frame: 0 minute to 5 days
  4. Part A: Q/FTime frame: 0 minute to 5 days
  5. Part A: AUC0-tauTime frame: 0 minute to 5 days
  6. Part A: CmaxTime frame: 0 minute to 5 days
  7. Part A: KinTime frame: 0 minute to 35 days
  8. Part A: KoutTime frame: 0 minute to 35 days
  9. Part A: KdegTime frame: 0 minute to 35 days
  10. Part A: SlopeTime frame: 0 minute to 35 days
  11. The proportion of subjects whose platelet count is ≥50×10^9/L within 24 hours before surgery and has increased by ≥20×10^9/L from baseline, and who have not received platelet transfusion or other treatments to raise platelet levels before surgeryTime frame: 0 minute to 11 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, affiliated with Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.